Pharmacokinetic Analysis of Ivermectin Repurposing for COVID-19 Treatment

A recent study found ivermectin reduced SARS-CoV-2 viral RNA by 99.98% in vitro at a 5 μM concentration. The dataset, from a paper by Ricardo Pena Silva of Universidad de Los Andes, discusses the significant pharmacokinetic challenge, as the highest reported human plasma concentration is only 0.28 μM, 18 times lower than the effective in vitro dose. It explores the gap between in vitro promise and in vivo feasibility for this widely available drug.

Use Cases

• Modeling drug concentration curves based on described human pharmacokinetic data for ivermectin.
• Analyzing the relationship between in vitro efficacy and achievable in vivo plasma concentrations mentioned in the paper.
• Researching formulation strategies like inhaled delivery to overcome systemic exposure limitations discussed in the text.

Strengths

• The description provides specific pharmacokinetic figures, including a 5 μM in vitro IC50 and a maximum human plasma concentration of 0.28 μM.
• It cites a concrete experimental result: a 99.98% reduction in SARS-CoV-2 viral RNA load at 48 hours in cell culture.

Limitations

• Row count and column-level documentation are absent; data structure must be inferred from the textual description.
• The dataset's origin from paperswithcode suggests it may be a summary or derived analysis, not raw experimental data.
• Last update date is unknown; freshness unverified.

Provenance

Source

Ricardo Pena Silva, Universidad de Los Andes, via paperswithcode.

Collection Method

Likely a compiled analysis or summary from published pharmacokinetic studies and clinical trial data.